Page last updated: 2024-08-17

levodopa and f 13640

levodopa has been researched along with f 13640 in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (50.00)24.3611
2020's3 (50.00)2.80

Authors

AuthorsStudies
Bardin, L; Cenci, MA; Depoortère, R; Iderberg, H; Kleven, MS; Koek, W; McCreary, AC; Newman-Tancredi, A; Varney, MA1
McCreary, AC; Newman-Tancredi, A; Varney, MA1
Brys, I; Halje, P; Newman-Tancredi, A; Petersson, P; Scheffer-Teixeira, R; Varney, M1
Brotchie, JM; Depoortere, R; Fox, SH; Johnston, TH; Newman-Tancredi, A1
Beardsley, PM; Bergman, J; Depoortère, R; Desai, RI; Newman-Tancredi, A; Paronis, CA; Varney, MA; Walentiny, DM1
Bouillot, C; Chaib, S; Depoortere, R; Levigoureux, E; Newman-Tancredi, A; Vidal, B; Zimmer, L1

Other Studies

6 other study(ies) available for levodopa and f 13640

ArticleYear
NLX-112, a novel 5-HT1A receptor agonist for the treatment of L-DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat.
    Experimental neurology, 2015, Volume: 271

    Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Brain; Catalepsy; Disease Models, Animal; Drug Interactions; Dyskinesia, Drug-Induced; Female; Haloperidol; Levodopa; Movement; Neurotransmitter Agents; Oxidopamine; Piperidines; Psychomotor Performance; Pyridines; Rats; Rats, Sprague-Dawley; Serotonin 5-HT1 Receptor Agonists; Serotonin Syndrome; Swimming; Vocalization, Animal

2015
The novel 5-HT1A receptor agonist, NLX-112 reduces l-DOPA-induced abnormal involuntary movements in rat: A chronic administration study with microdialysis measurements.
    Neuropharmacology, 2016, Volume: 105

    Topics: Animals; Anti-Dyskinesia Agents; Corpus Striatum; Cross-Over Studies; Dopamine; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Glutamic Acid; Levodopa; Male; Microdialysis; Oxidopamine; Parkinsonian Disorders; Piperidines; Pyridines; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Serotonin; Serotonin 5-HT1 Receptor Agonists

2016
Neurophysiological effects in cortico-basal ganglia-thalamic circuits of antidyskinetic treatment with 5-HT
    Experimental neurology, 2018, Volume: 302

    Topics: Animals; Basal Ganglia; Brain Waves; Cerebral Cortex; Disease Models, Animal; Dyskinesias; Electric Stimulation; Evoked Potentials; Female; Levodopa; Neural Pathways; Parkinson Disease, Secondary; Piperazines; Piperidines; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Serotonin 5-HT1 Receptor Agonists; Serotonin Antagonists; Thalamus

2018
The selective 5-HT
    Parkinsonism & related disorders, 2020, Volume: 78

    Topics: Amantadine; Animals; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Parkinsonian Disorders; Piperidines; Pyridines; Serotonin 5-HT1 Receptor Agonists

2020
NLX-112, a highly selective 5-HT
    Neuropharmacology, 2022, 06-01, Volume: 210

    Topics: Animals; Humans; Levodopa; Macaca; Male; Piperidines; Pyridines; Rats; Receptor, Serotonin, 5-HT1A; Serotonin 5-HT1 Receptor Agonists

2022
Multimodal imaging study of the 5-HT
    NeuroImage. Clinical, 2023, Volume: 39

    Topics: Animals; Dyskinesias; Fluorodeoxyglucose F18; Levodopa; Multimodal Imaging; Parkinson Disease; Rats; Receptor, Serotonin, 5-HT1A; Serotonin

2023